SynthesisDiabetes, obesity & metabolism2022

Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.

Francesco Zaccardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.